Table 6.

Previous reported series of mCRC with lung metastases

Series, year	Type of samples	Number of samples	KRAS mutation rate (%)	KRAS mutation prognostic value
Cejas et al., 2009 14	Primary + various metastatic sites	110	59	Shorter DFS
Tie et al., 2011 9	Various metastatic sites	100	49	Shorter LDFS
Kim et al., 2012 10	Primary + various metastatic sites	151	45	–
Schweiger et al., 2014 8	Lung metastases	44	48	Shorter LDFS
Yaeger et al., 2015 11	Primary + various metastatic sites	918	22	Shorter OS
Pereira et al., 2015 15	Primary + various metastatic sites	494	70	Shorter LDFS
Renaud et al., 2015 12	Lung metastases	180	52	Shorter OS
Morris et al., 2014 13	Primary + various metastatic sites	484	34	Shorter OS